2. McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. The American journal of surgical pathology. 1988;12(12):897–906.

3. Kalish J., Cooner W.H., Graham S.D.J. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology. 1994;43(5).

4. Djavan B., Zlotta A.R., Byttebier G., Shariat S., Omar M., Schulman C.C., et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. The Journal of urology. 1998;160(2):411-8; discussion 8–9.

5. Shen P., Zhao J., Sun G., Chen N., Zhang X., Gui H., et al. The roles of prostate-specific antigen (PSA) density, prostate volume, and their zone-adjusted derivatives in predicting prostate cancer in patients with PSA less than 20.0 ng/mL. Andrology. 2017;5(3):548–555.

6. Perez-Lanzac-Lorca A., Barco-Sanchez A., Romero E., Martinez-Peinado A., Lopez-Elorza F., Sanchez-Sanchez E., et al. Correlation between the complex PSA/total PSA ratio and the free PSA/total PSA ratio, sensitivity and specificity of both markers for the diagnosis of prostate cancer. Actas urologicas espanolas. 2013;37(8):498–503.

7. Filella X., Alcover J., Molina R., Rodriguez A., Carretero P., Ballesta A.M. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer. European journal of cancer. 1997;33(8):1226–1229.

8. Stephan C., Stroebel G., Heinau M., Lenz A., Roemer A., Lein M., et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Cancer. 2005;104(5):993-1003.

9. Fossati N., Buffi N.M., Haese A., Stephan C., Larcher A., McNicholas T.,et al. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives,%p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. European urology. 2015;68(1):132–138.

10. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer research. 1999;59(23):5975–5979.

11. Clarke R.A., Zhao Z., Guo A.Y., Roper K., Teng L., Fang Z.M., et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PloS one. 2009;4(3):e4995.

12. Salagierski M., Verhaegh G.W., Jannink S.A., Smit F.P., Hessels D., Schalken J.A. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. The Prostate. 2010;70(1):70–78.

13. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64(2):311–315; discussion 5–6.

14. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. The Journal of urology. 2008;179(4):1587–1592.

15. Lucas N., Day M.L. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. Journal of cellular biochemistry. 2009;106(6):967–974.

16. Baren J.P., Stewart G.D., Stokes A., Gray K., Pennington C.J.,O’Neill R., et al. mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma. Br J Cancer. 2012;107(1):143–149.

17. Dong D.D., Zhou H., Li G. ADAM15 targets MMP9 activity to promote lung cancer cell invasion. Oncology reports. 2015;34(5):2451–2460.

18. Toquet C, Colson A, Jarry A, Bezieau S, Volteau C, Boisseau P, et al. ADAM15 to alpha5beta1 integrin switch in colon carcinoma cells: a late event in cancer progression associated with tumor dedifferentiation and poor prognosis. International journal of cancer. 2012;130(2):278–287.

19. Ungerer C., Doberstein K., Burger C., Hardt K., Boehncke W.H.,Bohm B., et al. ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma. Biochemical and biophysical research communications. 2010;401(3):363–369.

20. White J.M. ADAMs: modulators of cell-cell and cell-matrix interactions. Current opinion in cell biology. 2003;15(5):598–606.

21. Najy A.J., Day K.C., Day M.L. ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction. Cancer research. 2008;68(4):1092–1009.

22. Burdelski C., Fitzner M., Hube-Magg C., Kluth M., Heumann A., Simon R., et al. Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia. 2017;19(4):279–287.

23. Cao D.L., Yao X.D. Advances in biomarkers for the early diagnosis of prostate cancer. Chinese journal of cancer. 2010;29(2):229–233.

24. Dhir R., Vietmeier B., Arlotti J., Acquafondata M., Landsittel D., Masterson R., et al. Early identification of individuals with prostate cancer in negative biopsies. The Journal of urology. 2004;171(4):1419–1423.

25. Paul B., Dhir R., Landsittel D., Hitchens M.R., Getzenberg R.H. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer research. 2005;65(10):4097–4100.

26. Leman E.S., Cannon G.W., Trock B.J., Sokoll L.J., Chan D.W., Mangold L., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 2007;69(4):714–720.

27. Yoshimoto M., Joshua A.M., Cunha I.W., Coudry R.A., Fonseca F.P., Ludkovski O., et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2008;21(12):1451–1460.

28. Mehra R., Tomlins S.A., Yu J., Cao X., Wang L., Menon A., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer research. 2008;68(10):3584–3590.

29. Hessels D., Smit F.P., Verhaegh G.W., Witjes J.A., Cornel E.B., Schalken J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007;13(17):5103–5108.

30. Luo J., Zha S., Gage W.R., Dunn T.A., Hicks J.L., Bennett C.J., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer research. 2002;62(8):2220–2226.

31. Sreekumar A., Laxman B., Rhodes D.R., Bhagavathula S., Harwood J., Giacherio D., et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. Journal of the National Cancer Institute. 2004;96(11):834–843.

32. Wei S., Dunn T.A., Isaacs W.B., De Marzo A.M., Luo J. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. The Prostate. 2008;68(13):1387–1395.

33. Kristiansen G., Fritzsche F.R., Wassermann K., Jager C., Tolls A., Lein M.,et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 2008;99(6):939–948.

34. Meiers I., Shanks J.H., Bostwick D.G. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology. 2007;39(3):29–304.

35. Ellinger J., Bastian P.J., Jurgan T., Biermann K., Kahl P., Heukamp L.C., et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 2008;71(1):161–167.

36. Derezinski P., Klupczynska A., Sawicki W., Palka J.A., Kokot Z.J. Amino Acid Profiles of Serum and Urine in Search for Prostate Cancer Biomarkers: a Pilot Study. International journal of medical sciences. 2017;14(1):1–12.

37. Cannon G.W., Mullins C., Lucia M.S., Hayward S.W., Lin V., Liu B.C., et al. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. The Journal of urology. 2007;177(2):610–614; discussion 4.

38. Kulkarni P., Uversky V.N. Cancer/Testis Antigens: «Smart» Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. International journal of molecular sciences. 2017;18(4).

39. Giorgio Ivan Russo, Federica Regis, Tommaso Castelli, Vincenzo Favilla, Salvatore Privitera, Raimondo Giardina, Sebastiano Cimino, Giuseppe Morgia. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and four-kallikrein panel score in predicting overall and high-grade prostate cancer. Clinical Genitourinary Cancer, 22 December 2016.

40. Rajnee Kanwal, Alexis R. Plaga, Xiaoqi Liu, Girish C. Shukla, Sanjay Gupta. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Letters xxx (2017) 1e12.

41. Zapatero A., Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy. 2013, https://clinicaltrials.gov/ct2/show/record/NCT01800058?term=CellSearch+Circulating+tumor+cells&rank=26

42. Sunil Parimi & Jenny J. Ko. Recent advances in circulating tumor. cells and cell-free DNA in metastatic prostate cancer: a review.

43. Helen M. Wise, Miguel A. Hermida and Nicholas R. Leslie. Prostate cancer, PI3K, PTEN and prognosis. Clinical Science (2017) 131, 197–210.

44. Xiao Z. Shen, Frank S. Ong, Ellen A. Bernstein, Tea Janjulia, WendellLamar B. Blackwell, Kandarp H. Shah, Brian L. Taylor, Romer A. Gonzalez-Villalobos, Sebastien Fuchs, and Kenneth E. Bernstein Non-tradicional roles of Angiotensin converting enzyme Hуpertension. 2012; 59(4): 763–768

45. Елисеева Ю.Е. Биоорганическая химия. 1998;24:232–240.

46. Hooper N.M. Angiotensin converting enzyme: implications from molecular biology for its physiological functions Int J Biochem. 1991;23(7-8):641–647.

47. Kryukova O.V., Tikhomirova V.E., Golukhova E.Z., Evdokimov V.V., Kalantarov G.F., Trakht I.N, et al. Tissue Specificity of Human Angiotensin I-Converting Enzyme. PloS one. 2015;10(11):e0143455.

48. HGNC database. Symbol report for ACE. HGNC database. 2014 https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2707

49. Singh U.S., Kumar M.V., Panda J.N. Angiotensin converting enzyme in semen and its possible role in capacitation. Andrologia. 1985 Sep-Oct;17(5):472–475.

50. Uemura H. Role of renin-angiotensin system in prostate cancer. Gan To Kagaku Ryoho. 2009;8(36):1228-33.

51. van Sande M., Nagamatsu A., Scharpé S., Neels H., Van Camp K. Tripeptidyl carboxypeptidase activity of angiotensin-converting enzyme in human tissues of the urogenital tract. Urol Int.

52. Ruiter V.L., Van Duijn C.M., Stricker B.H. The ACE insertion/deletion polymorphism and risk of cancer, a review and meta-analysis of the literature. Curr Cancer Drug Targets. 2011.

53. Ripka J.E., Ryan J.W., Valido F.A., Chung A.Y., Peterson C.M., Urry R.L.N-glycosylation of forms of angiotensin converting enzyme from four mammalian species. Biochemical and biophysical research communications. 1993;196(2):503–508.

54. Liu T., Qian W.J., Gritsenko M.A., Camp D.G., 2nd, Monroe M.E.,Moore R. et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. Journal of proteome research. 2005;4(6):2070–2080.

55. Kryukova O.V., Tikhomirova V.E., Golukhova E.Z., Evdokimov V.V. et al. Tissue Specificity of Human Angiotensin I-Converting Enzyme PLoS ONE 23 Nov 2015, 10(11):e0143455.